NRx Pharmaceuticals, Inc. NRXP
Regular-session close
After hours · Nov 20, 7:58 PM ET
- YTD
- -20.66%
- 1 year
- +5.91%
5D +0.03 (+1.42%)
- Market cap
- 95.31M
- EPS (ttm)
- -0.33
- Shares out
- 12.09M
- Forward P/E
- -1.12
- YTD return
- -20.66%
- 1-year return
- +5.91%
- 50-day average
- 1.28
- 200-day average
- 2.53
- Volume
- 1.48M
- Avg volume
- 1.06M
- Open
- 2.53
- Previous close
- 2.55
- Day's range
- 2.14 – 2.53
- 52-week range
- 1.68 – 4.62
- Beta
- 1.27
- Price target
- 31.67 (+1372.9%)
Key statistics
- Enterprise value
- 18.64M
- Free cash flow
- -7.35M
- Total cash
- 1.90M
- Total debt
- 7.65M
- Short % of float
- 7.69%
Fundamental scorecard
4 of 25 checks passed on NRXP’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 2 of 5
- Profitability 0 of 5
- Financial health 2 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.81 | -0.15 | +0.66 | +81.48% |
| Aug 14, 2024 | Jun 1, 2024 | -0.81 | -0.75 | +0.06 | +7.41% |
| Aug 14, 2024 | Jun 1, 2024 | -0.81 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -0.74 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Mar 29, 2024 | Dec 1, 2023 | -0.70 | -0.50 | +0.20 | +28.57% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 2, 2024 | Ascendiant Capital | main | Buy | Buy |
| Nov 25, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 15, 2024 | D. Boral Capital | main | Buy | Buy |
| Oct 30, 2024 | EF Hutton | main | Buy | Buy |
| Oct 21, 2024 | EF Hutton | init | — | Buy |
| Sep 12, 2024 | Ascendiant Capital | main | Buy | Buy |
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- nrxpharma.com
News
NRx Pharmaceuticals, Inc. (NRXP) Q3 2026 Earnings Call Transcript
What NRx Pharmaceuticals (NRXP) Said on Its Q3 Earnings Call
NRx Pharmaceuticals (Nasdaq: NRXP) Reports Third Quarter 2026 Financial Results and Provides Corporate Update NRX Pharmaceuticals Q3 EPS $(0.05) Beats $(0.21) Estimate, Sales $1.159M Miss $1.300M Estimate
NRx Pharmaceuticals, Inc. (NRXP) Reports Q3 Loss, Misses Revenue Estimates
Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $51
12 Health Care Stocks Moving In Friday's Pre-Market Session NRx Pharmaceuticals Receives FDA Approval Of Its Abbreviated New Drug Application For Preservative-Free Ketamine
Why Civeo Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
Your note
Sign in to keep a note on NRXP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GOROVITZ AARON | Director | Purchase | Aug 29, 2023 | 0 |
| HURVITZ CHAIM | Director | Purchase | Aug 29, 2023 | 2,214,790 |
| JAVITT JONATHAN C | Chairman of the Board | Purchase | Dec 16, 2024 | 1,516,830 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 1.99% | 240,316 | 341.25K | Sep 29, 2024 |
| Anson Funds Management LP | 1.18% | 142,525 | 202.38K | Sep 29, 2024 |
| AdvisorShares Investments, LLC | 1.08% | 130,085 | 184.72K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.64% | 77,341 | 109.82K | Sep 29, 2024 |
| Sabby Management, LLC | 0.29% | 35,049 | 49.77K | Sep 29, 2024 |
| Blackrock Inc. | 0.24% | 29,075 | 41.29K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 2.41% | 291,271 | 413.60K | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 1.60% | 193,423 | 274.66K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.39% | 46,893 | 66.59K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.36% | 43,510 | 61.78K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.09% | 10,327 | 14.66K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.08% | 10,005 | 14.21K | Oct 30, 2024 |
